

Figure S1. Effects of miR-351-5p on LPS-induced inflammation and oxidative stress in the livers. (A) Relative ROS, MDA and protein carbonyls levels in the livers with or without miR-351-5p antagonomir treatment upon LPS challenge (n=6). (B) TNF- α levels in the livers measured by ELISA (n=6). (C) MPO activity in the livers with or without miR-351-5p antagonomir treatment upon LPS challenge (n=6). (D) Relative ROS, MDA and protein carbonyls levels in the livers with or without miR-351-5p agomir treatment upon LPS challenge (n=6). (E) TNF- α levels in the livers measured by ELISA (n=6). (F) MPO activity in the livers with or without miR-351-5p agomir treatment upon LPS challenge (n=6). All data are expressed as mean \pm SD. *P<0.05 with comparisons shown by lines. miR, microRNA; LPS, lipopolysaccharide; ROS, reactive oxygen species; MDA, malondialdehyde; MPO, myeloperoxidase; NC, negative control.




Figure S2. Effects of miR-351-5p on LPS-induced inflammation and oxidative stress in the brains. (A) Relative ROS, MDA and protein carbonyls levels in the brains with or without miR-351-5p antagonomir treatment upon LPS challenge (n=6). (B) TNF- α levels in the brains measured by ELISA (n=6). (C) MPO activity in the brains with or without miR-351-5p antagonomir treatment upon LPS challenge (n=6). (D) Relative ROS, MDA and protein carbonyls levels in the brains with or without miR-351-5p agomir treatment upon LPS challenge (n=6). (E) TNF- α levels in the brains measured by ELISA (n=6). (F) MPO activity in the brains with or without miR-351-5p agomir treatment upon LPS challenge (n=6). All data are expressed as mean \pm SD. *P<0.05 with comparisons shown by lines. miR, microRNA; LPS, lipopolysaccharide; ROS, reactive oxygen species; MDA, malondialdehyde; MPO, myeloperoxidase; NC, negative control.

